Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 6,446 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed No phase listed Observational Accepts healthy volunteers

Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis

NCT05324878
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure
Interventions
Training
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Denver, Colorado • Beverly, Massachusetts • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 4, 2026, 5:34 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Fernald Community Cohort -18 Year Observational Study

NCT02295085
View directory record Official record
Conditions
Cancer, Renal Failure, Diabetes, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years and older
Enrollment
9,782 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Nov 4, 2026, 5:34 AM EST
Completed No phase listed Observational

Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy

NCT03958643
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 4, 2026, 5:34 AM EST
Completed Phase 4 Interventional Results available

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

NCT00911625
View directory record Official record
Conditions
Type 2 Diabetes, Renal Insufficiency
Interventions
0.5 units/kg daily insulin, 0.25 units/kg daily insulin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Nov 4, 2026, 5:34 AM EST
Recruiting Phase 1 Interventional

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776
View directory record Official record
Conditions
Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Interventions
sparsentan, No sparsentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 4, 2026, 5:34 AM EST
Completed Not applicable Interventional

Virtual Nephrologist

NCT06841016
View directory record Official record
Conditions
Chronic Kidney Disease(CKD)
Interventions
Virtual Nephrologist
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 4, 2026, 5:34 AM EST
Terminated Not applicable Interventional

INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma

NCT03692338
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Exercise
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Nov 4, 2026, 5:34 AM EST
Active, not recruiting Not applicable Interventional

Curcumin in Kidney Transplant Recipients

NCT03935958
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Curcumin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 5:34 AM EST
Completed No phase listed Observational

Drug Sensitivity and Mutation Profiling

NCT04956198
View directory record Official record
Conditions
Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Wilms Tumor, Sarcoma, Spindle Cell, Sarcoma Rhabdoid, Childhood Sarcoma of Soft Tissue
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
Up to 21 Years
Enrollment
14 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 4, 2026, 5:34 AM EST
Terminated Phase 3 Interventional

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

NCT00275314
View directory record Official record
Conditions
Kidney Transplant
Interventions
Valganciclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 68 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Nov 4, 2026, 5:34 AM EST
Terminated Phase 2 Interventional

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

NCT00229684
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Washington D.C., District of Columbia • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Nov 4, 2026, 5:34 AM EST
Active, not recruiting Not applicable Interventional

MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence

NCT05735743
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Motivational interviewing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Philadelphia, Pennsylvania • Philadelphia, PA 19123, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 4, 2026, 5:34 AM EST
Terminated Not applicable Interventional Results available

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00727532
View directory record Official record
Conditions
Hereditary Clear Cell Renal Cell Carcinoma, Kidney Cancer
Interventions
Sorafenib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Nov 4, 2026, 5:34 AM EST
Active, not recruiting Phase 3 Interventional

TARGET BP I Clinical Trial

NCT02910414
View directory record Official record
Conditions
Hypertension
Interventions
Dehydrated alcohol, Peregrine System Kit (Sham Procedure)
Drug · Device
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 4, 2026, 5:34 AM EST
Terminated No phase listed Observational

Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care

NCT04267016
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
TruGraf Testing - Peripheral blood gene expression profiling
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Nov 4, 2026, 5:34 AM EST
Terminated Phase 4 Interventional Results available

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

NCT00522548
View directory record Official record
Conditions
Transplants and Implants
Interventions
Enteric coated mycophenolate sodium, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 4, 2026, 5:34 AM EST
Withdrawn No phase listed Observational

Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography

NCT03806725
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation, Contrast Media
Interventions
Intravenous administration of iodinated contrast medium for coronary CT angiography
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Nov 4, 2026, 5:34 AM EST
Terminated No phase listed Observational

Allosure in Simultaneous Pancreas Kidney Transplant

NCT04777617
View directory record Official record
Conditions
Kidney Pancreas Transplant
Interventions
DD-cfDNA
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Nov 4, 2026, 5:34 AM EST
Active, not recruiting Phase 2 Interventional

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987
View directory record Official record
Conditions
APOL1-Mediated Kidney Disease
Interventions
AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
Combination Product · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 4, 2026, 5:34 AM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

NCT05889806
View directory record Official record
Conditions
Oncology, Hematologic Malignancy, Gastro-Intestinal Disorder, Autoimmune Diseases, Pregnancy Related, Infectious Disease, Cardiovascular Diseases, Genitourinary Disease, Renal Disease
Interventions
Observational Study Only. NO Intervention.
Other
Lead sponsor
Audubon Bioscience
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2043
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Nov 4, 2026, 5:34 AM EST
Completed Phase 3 Interventional

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

NCT00048152
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Corticosteroids, Neoral, Zenapax, mycophenolate mofetil [CellCept]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 4, 2026, 5:34 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

NCT04831138
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 4, 2026, 5:34 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Kidney Fibrosis and MRI

NCT03964948
View directory record Official record
Conditions
Kidney Diseases
Interventions
Kidney MRI
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 25 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Nov 4, 2026, 5:34 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 4, 2026, 5:34 AM EST